News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
810,358 Results
Type
Article (72793)
Company Profile (463)
Press Release (737076)
Multimedia
Podcasts (195)
Webinars (34)
Section
Business (216932)
Career Advice (3287)
Deals (38074)
Drug Delivery (158)
Drug Development (87844)
Employer Resources (192)
FDA (18197)
Job Trends (16650)
News (373644)
Policy (38102)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3021)
Academic (1)
Accelerated approval (45)
Adcomms (37)
Allergies (173)
Alliances (54724)
ALS (206)
Alzheimer's disease (1884)
Antibody-drug conjugate (ADC) (414)
Approvals (18429)
Artificial intelligence (690)
Autoimmune disease (249)
Automation (53)
Bankruptcy (394)
Best Places to Work (12505)
BIOSECURE Act (23)
Biosimilars (219)
Biotechnology (318)
Bladder cancer (185)
Brain cancer (73)
Breast cancer (726)
Cancer (5638)
Cardiovascular disease (502)
Career advice (2800)
Career pathing (46)
CAR-T (330)
CDC (71)
Celiac Disease (2)
Cell therapy (890)
Cervical cancer (43)
Clinical research (74882)
Collaboration (2082)
Company closure (6)
Compensation (1303)
Complete response letters (91)
COVID-19 (3011)
CRISPR (110)
C-suite (1054)
Cystic fibrosis (160)
Data (7251)
Decentralized trials (3)
Denatured (71)
Depression (176)
Dermatology (59)
Diabetes (591)
Diagnostics (7360)
Digital health (56)
Diversity (13)
Diversity, equity & inclusion (48)
Drug discovery (341)
Drug pricing (235)
Drug shortages (34)
Duchenne muscular dystrophy (286)
Earnings (90726)
Editorial (71)
Employer branding (23)
Employer resources (167)
Events (126153)
Executive appointments (1110)
FDA (21758)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (30)
Funding (1729)
Gene editing (237)
Generative AI (64)
Gene therapy (740)
GLP-1 (1199)
Government (5355)
Grass and pollen (8)
Guidances (400)
Healthcare (20781)
HIV (79)
Huntington's disease (58)
IgA nephropathy (96)
Immunology and inflammation (327)
Immuno-oncology (92)
Indications (158)
Infectious disease (3357)
Inflammatory bowel disease (220)
Inflation Reduction Act (15)
Influenza (139)
Intellectual property (282)
Interviews (608)
IPO (17580)
IRA (59)
Job creations (4514)
Job search strategy (2296)
JPM (70)
Kidney cancer (19)
Labor market (97)
Layoffs (667)
Leadership (45)
Legal (9463)
Liver cancer (106)
Longevity (29)
Lung cancer (757)
Lymphoma (417)
Machine learning (55)
Management (64)
Manufacturing (999)
MASH (194)
Medical device (15096)
Medtech (15179)
Mergers & acquisitions (21675)
Metabolic disorders (1587)
mRNA (212)
Multiple sclerosis (182)
NASH (24)
Neurodegenerative disease (436)
Neuropsychiatric disorders (116)
Neuroscience (3409)
Neurotech (2)
NextGen: Class of 2026 (7487)
Non-profit (5088)
Now hiring (69)
Obesity (776)
Opinion (352)
Ovarian cancer (190)
Pain (248)
Pancreatic cancer (267)
Parkinson's disease (364)
Partnered (37)
Patents (582)
Patient recruitment (620)
Peanut (64)
People (64597)
Pharmaceutical (93)
Pharmacy benefit managers (36)
Phase 1 (23275)
Phase 2 (32719)
Phase 3 (24611)
Pipeline (7320)
Policy (366)
Postmarket research (3034)
Preclinical (10260)
Press Release (72)
Prostate cancer (290)
Psychedelics (61)
Radiopharmaceuticals (330)
Rare diseases (1115)
Real estate (6869)
Recruiting (78)
Regulatory (28609)
Reports (58)
Research institute (2734)
Resumes & cover letters (527)
Rett syndrome (33)
RNA editing (22)
RSV (95)
Schizophrenia (178)
Series A (291)
Series B (214)
Service/supplier (15)
Sickle cell disease (115)
Special edition (29)
Spinal muscular atrophy (182)
Sponsored (52)
Startups (4156)
State (2)
Stomach cancer (21)
Supply chain (128)
Tariffs (102)
The Weekly (122)
Vaccines (1224)
Venture capital (111)
Weight loss (529)
Women's health (113)
Worklife (23)
Date
Last 7 days (674)
Last 30 days (2676)
Last 365 days (32008)
2026 (8553)
2025 (32386)
2024 (37520)
2023 (42413)
2022 (53765)
2021 (58534)
2020 (57422)
2019 (50835)
2018 (38747)
2017 (36323)
2016 (36728)
2015 (42526)
2014 (36272)
2013 (31705)
2012 (33583)
2011 (33969)
2010 (32164)
Location
Africa (1110)
Alabama (99)
Alaska (7)
Arizona (338)
Arkansas (14)
Asia (48580)
Australia (8203)
California (12700)
Canada (3587)
China (1332)
Colorado (545)
Connecticut (552)
Delaware (381)
Europe (110674)
Florida (1902)
Georgia (417)
Hawaii (4)
Idaho (67)
Illinois (1049)
India (87)
Indiana (591)
Iowa (23)
Japan (505)
Kansas (135)
Kentucky (49)
Louisiana (43)
Maine (85)
Maryland (1564)
Massachusetts (9262)
Michigan (378)
Minnesota (717)
Mississippi (7)
Missouri (153)
Montana (37)
Nebraska (30)
Nevada (142)
New Hampshire (89)
New Jersey (3429)
New Mexico (33)
New York (3354)
North Carolina (1712)
North Dakota (10)
Northern California (6211)
Ohio (390)
Oklahoma (25)
Oregon (47)
Pennsylvania (2546)
Puerto Rico (26)
Rhode Island (52)
South America (1491)
South Carolina (78)
South Dakota (1)
Southern California (4975)
Tennessee (204)
Texas (2017)
United States (45547)
Utah (383)
Vermont (1)
Virginia (317)
Washington D.C. (86)
Washington State (1039)
West Virginia (4)
Wisconsin (140)
Wyoming (2)
810,358 Results for "productos medix s a de s v".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Podcast
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
The obesity market and Most Favored Nation drug pricing were among the topics de jour at the J.P. Morgan Healthcare Conference last week, while smaller biotechs sought to assure investors that their regulatory ducks are in a row; Novo Nordisk’s oral obesity pill got off to a hot start while the FDA delayed a decision on Eli Lilly’s investigational offering; and SpyGlass Pharma and AgomAb Therapeutics join the 2026 IPO club.
January 21, 2026
·
1 min read
·
Heather McKenzie
Drug pricing
Trump’s MFN Pricing Expected To Delay More European Drug Launches
Following Insmed’s decision to hold off on launching a newly approved lung disease drug in Europe, experts anticipate more companies will do the same as they seek to avoid price erosion in the U.S. Will Chinese biotechs fill the void?
April 1, 2026
·
3 min read
·
Nick Paul Taylor
Podcast
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
UniQure and REGENXBIO are both dealing with FDA setbacks for their respective gene therapies, as regulatory experts question the FDA’s decision-making processes; CBER director Vinay Prasad is under probe for allegedly fostering a toxic workplace; Sarepta CEO Doug Ingram is stepping down after several years of tumult at the top of the muscular dystrophy–focused company; and Eli Lilly again tops Novo Nordisk in a weight loss trial.
March 4, 2026
·
1 min read
·
Heather McKenzie
Cardiovascular disease
Merck’s Cholesterol Pill Delivers ‘Antibody-Like Efficacy’ After Earning FDA Voucher
Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner’s National Priority Voucher.
March 31, 2026
·
2 min read
·
Tristan Manalac
Rare diseases
Denali’s Hunter Syndrome Candidate in the Spotlight After REGENXBIO Rejection
The Hunter syndrome space suffered a setback in February when the FDA turned down REGENXBIO’s investigational gene therapy, raising urgent questions about whether competitor Denali Therapeutics can clear the agency’s bar next month.
March 16, 2026
·
6 min read
·
Ben Hargreaves
Podcast
Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More
Gilead continues its dealmaking spree in the sizzling hot space of I&I as Johnson & Johnson, along with partner Protagonist, notched an FDA approval for a new psoriasis drug. Plus, Aurinia Pharmaceuticals gets a new C-suite, FDA releases draft guidance on non-animal models and the CDC’s vaccine advisory committee is not being disbanded after all.
March 25, 2026
·
1 min read
·
Heather McKenzie
Press Releases
Battelle Awarded U.S. EPA STREAMS V Contract to Deliver Nationwide Scientific, Technical, Research, Engineering, and Modeling Support
February 6, 2026
·
2 min read
Podcast
Kennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter
Heath Secretary Robert F. Kennedy Jr.’s efforts to overhaul vaccine policy are likely illegal, a Massachusetts District Court Judge ruled; Structure’s GLP-1 weight loss pill succeeds in Phase 2 while Rhythm’s Phase 3 basket trial fails to find the beat; Eli Lilly warns of potential safety risks of taking compounded tirzepatide, and Novo Nordisk is hit with an FDA warning letter regarding adverse events potentially linked to Ozempic.
March 18, 2026
·
1 min read
·
Heather McKenzie
Rare disease
UniQure Eyes Phase 3 for Huntington’s Gene Therapy Despite Makary’s Apparent Criticism
Days after FDA Commissioner Marty Makary appeared to malign uniQure’s AMT-130 in an interview with
CNBC
, the agency confirmed to the biotech that a sham surgery–controlled study is needed before submitting the gene therapy for approval.
March 2, 2026
·
3 min read
·
Heather McKenzie
Breast cancer
Pfizer’s Ibrance Heir Reduces Risk of Death in Phase 2 Breast Cancer Test
Pfizer has a lofty goal for the CDK4 inhibitor atirmociclib, the New York pharma’s answer to Ibrance’s loss of patent protection next year. In 2025, Ibrance led Pfizer’s oncology portfolio with $1.04 billion in sales.
March 17, 2026
·
1 min read
·
Annalee Armstrong
1 of 81,036
Next